Laurie Stelzer
Director/Board Member at PMV PHARMACEUTICALS, INC.
Net worth: - $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Mack | M | 62 | 11 years | |
Jeffrey Henderson | M | 59 | 9 years | |
Russell Cox | M | 60 | 9 years | |
Cameron Turtle | M | 34 | 1 years | |
Carol Gallagher | M | 59 | 2 years | |
Michael Carulli | M | 74 | 4 years | |
Arnold Levine | M | 84 | 11 years | |
Richard Heyman | M | 66 | 4 years | |
Amit Munshi | M | 56 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Deepika Jalota | M | 48 | 5 years | |
Scott Burrows | M | 47 | 1 years | |
Kirsten Flowers | F | 49 | 2 years | |
Heidy Abreu King-Jones | F | 41 | 1 years | |
Brian Goodman | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Michael Henderson | M | 34 | 1 years | |
Bernadette Connaughton | F | 65 | 6 years | |
Charles Baum | M | 65 | 3 years | |
Peter Harwin | M | 38 | 1 years | |
Tomas Kiselak | M | 38 | 1 years | |
Timothy J. Smith | M | - | 3 years | |
Tyler Jacks | M | 63 | 12 years | |
Robert Ticktin | M | 62 | - | |
Ciaran Lawlor | M | - |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 3 years |
Shibu Sleeba | M | - | 4 years | |
Laura De Leon | F | - | 5 years | |
Crystal Zuckerman | F | - | 4 years | |
Mira Huyghe | F | - | 1 years | |
Joshua Friedman | M | - | 1 years | |
Marc Fellous | M | - | 2 years | |
Deanna Nguyen | M | - | 1 years | |
Lauren Harshman | F | - | 3 years | |
Amy Marinne Fox | F | - | 4 years | |
Lamine Mbow | M | - | 3 years | |
Steve Knowles | M | - | 6 years | |
Paul Fehlner | M | 61 | 1 years | |
Mark Mckenna | M | 48 | - | |
Binh Vu | M | 56 | - | |
Scott W. Rowlinson | M | 56 | 10 years | |
Jeffrey Albers | M | 52 | 1 years | |
Matt Roden | M | 53 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | 1 years |
Morana Jovan-Embiricos | M | 57 |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | - |
Brian Connolly | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
J. Goater | M | 48 | 6 years | |
Dave Grayzel | M | 56 | 9 years | |
Kathryn Falberg | F | 63 | 9 years | |
Jessica Fees | F | 52 | 8 years | |
Harry Leonhardt | M | 67 | 5 years | |
Michael E. Paolucci | M | 64 | 5 years | |
Winston Kung | M | 48 | 7 years | |
Benjamin Hickey | M | 50 | 5 years | |
Denice Torres | F | 64 | 2 years | |
Vickie Reed | F | 62 | 9 years | |
Masaru Matsuda | M | 53 | 3 years | |
David Ramsay | M | 59 | 12 years | |
Liisa I. Nogelo | F | 53 | - | |
Robert Azelby | M | 56 | 5 years | |
Albert Kildani | M | - | - | |
David Meek | M | 59 | 2 years | |
Craig Shepherd | M | - | 7 years | |
Theresa R. Boni | F | 56 | - | |
Thilo Schroeder | M | 42 | 3 years | |
Joan Schmidt | F | 60 | - | |
Thomas Heineman | M | - | 2 years | |
Homa Yeganegi | F | - | - | |
Nawal Ouzren | F | 45 | 1 years | |
Temre Johnson | M | - | 5 years | |
George Morrow | M | 72 | 10 years | |
Katharine Knobil | M | 60 | 2 years | |
Ramy Ibrahim | M | 49 | 4 years | |
Randal Kirk | M | 70 | 11 years | |
Aaron Ondrey | M | 48 | 2 years | |
James Daly | M | 63 | 9 years | |
Peter Thompson | M | 64 | 8 years | |
Steven W. Spector | M | 59 | 19 years | |
Charles Sigal | M | 72 | 5 years | |
Manmeet Singh Soni | M | 46 | 3 years | |
Frederick Gluck | M | 88 | 13 years | |
Randall E. Woods | M | 72 | 13 years | |
Henry Fuchs | M | 66 | 11 years | |
Daniel Lynch | M | 65 | 5 years | |
Steven Galson | M | 67 | - | |
William J. Fallon | M | - | 14 years | |
Jim Mazzola | M | - | 3 years | |
Seth D. Lewis | M | - | - | |
Alison Lawton | F | 62 | 4 years | |
Armen Shanafelt | M | 64 | 9 years | |
Christopher Cabell | M | 54 | 3 years | |
Cameron McDonough | M | 53 | 4 years | |
Ann Merchant | F | 59 | 17 years | |
Deborah Wenkert | M | 65 | 6 years | |
Richard Williams | M | 55 | 2 years | |
Christophe Quéva | M | 57 | 5 years | |
Helen Torley | M | 61 | 8 years | |
Roger Perlmutter | M | 71 | 11 years | |
Philip Astley-Sparke | M | 52 | - | |
David Lacey | M | 71 | 17 years | |
Marc D. Better | M | 68 | 5 years | |
Olivier Leonetti | M | 59 | 3 years | |
Iain Dukes | M | 65 | 3 years | |
Richard Davies | M | 62 | 9 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Laurie Stelzer
- Personal Network